semaglutide oral approval FDA approves first-ever GLP-1RA for obesity and chronic weight management. Meet Wegovy (semaglutide) tablets. https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-wegovy-pill-the-first-and-only- oral-glp-1-for-weight-loss-in-adults The Dermatology Digest | The

Patients carrying the GLP1R rs6923761 variant, for example, may require dose adjustments or complementary agents to achieve target weight loss, while others with GIPR rs1800437 variants show enhanced response to tirzepatide dual-agonist therapy

Q12: Is this medical advice

According to the FDA prescribing information, nausea occurs in approximately 24-30% of patients at higher doses, with rates generally increasing with dose escalation

"Lean mass" on a DXA scan (the imaging method used in these trials) includes water, organs, and connective tissue, not just skeletal muscle, so the actual muscle-only share is somewhat smaller than the lean-mass figure suggests